Assessing the cost-effectiveness of hepatitis C screening strategies in France

JOURNAL OF HEPATOLOGY

卷:69

Article

Deuffic-Burban, Sylvie^1,2  Huneau, Alexandre¹  Verleene, Adeline¹  Brouard, Cecile³  Pillonel, Josiane³  Le Strat, Yann³  Cossais, Sabrina¹  Roudot-Thoraval, Francoise⁴  Canvas, Valerie⁵  Mathurin, Philippe^2,5  Dhumeaux, Daniel⁶  Yazdanpanah, Yazdan^1,7 

[1] Univ Paris Diderot, Sorbonne Paris Cite, INSERM, IAME,UMR 1137, Paris, France

[2] Univ Lille, LIRIC, CHU Lille, Inserm,U995, Lille, France

[3] Sante Publ France, St Maurice, France

[4] Hop Henri Mondor, Serv Sante Publ, Creteil, France

[5] CHRU Lille, Hop Huriez, Serv Malad Appareil Digestif & Nutr, Lille, France

[6] Hop Henri Mondor, Inserm U955, Creteil, France

[7] Hop Bichat Claude Bernard, Serv Malad Infect & Trop, Paris, France

关键词: Chronic hepatitis C;    Cohort Markov model;    Effectiveness analysis;    Cost-effectiveness analysis;    Interferon-free direct-acting antiviral agents;    Screening;   

DOI  :  10.1016/j.jhep.2018.05.027

来源: Elsevier

【 摘 要 】

Background & Aims: In Europe, hepatitis C virus (HCV) screening still targets people at high risk of infection. We aim to determine the cost-effectiveness of expanded HCV screening in France. Methods: A Markov model simulated chronic hepatitis C (CHC) prevalence, incidence of events, quality-adjusted life years (QALYs), costs and incremental cost-effectiveness ratio (ICER) in the French general population, aged 18 to 80 years, undiagnosed for CHC for different strategies: S1 = current strategy targeting the at risk population; S2 = S1 and all men between 18 and 59 years; S3 = S1 and all individuals between 40 and 59 years; S4 = S1 and all individuals between 40 and 80 years; S5 = all individuals between 18 and 80 years (universal screening). Once CHC was diagnosed, treatment was initiated either to patients with fibrosis stage or regardless of fibrosis. Data were extracted from published literature, a national prevalence survey, and a previously published mathematical model. ICER were interpreted based on one or three times French GDP per capita (sic32,800). Results: Universal screening led to the lowest prevalence of CHC and incidence of events, regardless of treatment initiation. When considering treatment initiation to patients with fibrosis >= F2, targeting all people aged 40-80 was the only cost-effective strategy at both thresholds (sic26,100/QALY). When we considered treatment for all, although universal screening of all individuals aged 18-80 is associated with the highest costs, it is more effective than targeting all people aged 40-80, and costeffective at both thresholds (sic31,100/QALY). Conclusions: In France, universal screening is the most effective screening strategy for HCV. Universal screening is cost-effective when treatment is initiated regardless of fibrosis stage. From an individual and especially from a societal perspective of HCV eradication, this strategy should be implemented. Lay summary: In the context of highly effective and well tolerated therapies for hepatitis C virus that are now recommended for all patients, a reassessment of hepatitis C screening strate-gies is needed. An effectiveness and cost-effectiveness study of different strategies targeting either the at-risk population, specific ages or all individuals was performed. In France, universal screening is the most effective strategy and is cost-effective when treatment is initiated regardless of fibrosis stage. From an individual and especially from a societal perspective of hepatitis C virus eradication, this strategy should be implemented. (C) 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

【 授权许可】

Free